DeepMed Research

Ezogabine

Generic Name: Ezogabine

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈FN_₃O_₂

CAS Number: 150812-12-7

Unique Ingredient Identifier: 12G01I6BBU

Background: Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.

Indication: Adjuvant treatment of partial-onset seizures.

Associated Conditions: Refractory Partial Onset Seizures

Clinical Trials

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase 3

Terminated

Conditions: Nervous System Diseases
Epilepsy in Children
Disease
Central Nervous System Diseases
Epileptic Syndromes
Epilepsy; Seizure
Epilepsy
Brain Diseases

Interventions: Drug: XEN496

First Posted Date: 2021-06-03

Last Posted Date: 2025-02-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04912856

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺
Sydney Children's Hospital, Sydney, New South Wales, Australia
🇧🇪
Universitair Ziekenhuis Antwerpen - Dienst Kinderneurologie, Edegem, Antwerpen, Belgium

and more 1 locations

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase 3

Terminated

Conditions: Disease
Epilepsy
Epilepsy in Children
Epilepsy; Seizure
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes

Interventions: Drug: Placebo
Drug: XEN496

First Posted Date: 2020-11-20

Last Posted Date: 2024-08-23

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04639310

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Anne & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 17 locations

Study to Treat Major Depressive Disorder With a New Medication

Phase 2

Completed

Conditions: Depressive Disorder
Anhedonia

Interventions: Drug: Placebos
Drug: Ezogabine

First Posted Date: 2017-02-06

Last Posted Date: 2020-10-23

Lead Sponsor: James Murrough

Target Recruit Count: 45

Registration Number: NCT03043560

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Ezogabine
Drug: Placebo

First Posted Date: 2015-05-21

Last Posted Date: 2019-08-28

Lead Sponsor: Brian Wainger

Target Recruit Count: 65

Registration Number: NCT02450552

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States

and more 9 locations

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Phase 2

Completed

Conditions: Major Depressive Disorder
Depression

Interventions: Drug: ezogabine

First Posted Date: 2014-05-29

Last Posted Date: 2019-04-16

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 18

Registration Number: NCT02149836

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: retigabine
Drug: placebo

First Posted Date: 2013-04-04

Last Posted Date: 2014-12-02

Lead Sponsor: University Hospital of Mont-Godinne

Target Recruit Count: 15

Registration Number: NCT01823159

Locations: 🇧🇪
CHU Mont-Godinne, Yvoir, Namur, Belgium

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Retigabine IR

First Posted Date: 2013-01-28

Last Posted Date: 2020-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01777139

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Phase 1

Withdrawn

Conditions: Epilepsy, Partial

Interventions: Drug: Retigabine

First Posted Date: 2012-09-25

Last Posted Date: 2018-09-17

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01691872

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

Phase 3

Terminated

Conditions: Epilepsy

Interventions: Drug: Retigabine 600mg/day
Other: Placebo
Drug: Retigabine 900mg/day

First Posted Date: 2012-07-24

Last Posted Date: 2018-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 76

Registration Number: NCT01648101

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Retigabine / Ezogabine

First Posted Date: 2011-11-29

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 8

Registration Number: NCT01480609

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy